Home › Research › Treatments
A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500)
Wilcock G, Möbius HJ, Stöffler A, MMM 500 group.. International clinical psychopharmacology, 2002-11-01
Topic: Risk, prevention and care in population studies
The aim of the reported trial was to investigate the safety and efficacy of memantine in mild to moderate vascular dementia (VaD). This was a 28-week, double-blind, parallel, randomized controlled trial of memantine 20 mg daily versus placebo which was conducted in 54 centres in the UK. Memantine is a uncompetitive, moderate affinity N-methyl-D-aspartate receptor antagonist.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Wilcock, G., Möbius, H. J., Stöffler, A., & MMM 500 group. (2002). A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). International clinical psychopharmacology. https://doi.org/10.1097/00004850-200211000-00005
Vancouver
Wilcock G, Möbius HJ, Stöffler A, MMM 500 group. A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500). International clinical psychopharmacology. 2002. doi:10.1097/00004850-200211000-00005. PMID: 12409683.
BibTeX
@article{wilcock2002-12409683,
author = {Wilcock, G. and Möbius, H. J. and Stöffler, A. and {MMM 500 group}},
title = {{A double-blind, placebo-controlled multicentre study of memantine in mild to moderate vascular dementia (MMM500)}},
journal = {International clinical psychopharmacology},
year = {2002},
doi = {10.1097/00004850-200211000-00005},
pmid = {12409683},
url = {https://doi.org/10.1097/00004850-200211000-00005}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. Check the citation against the original before you use it.
Key findings
- This was a 28-week, double-blind, parallel, randomized controlled trial of memantine 20 mg daily versus placebo which was conducted in 54 centres in the UK.
- Memantine is a uncompetitive, moderate affinity N-methyl-D-aspartate receptor antagonist.
- Patients with a diagnosis of probable VaD and Mini Mental State Examination total scores between 10 and 22 were eligible for inclusion.
- Primary efficacy parameters were the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-cog) and the Clinical Global Impression of Change (CGI-C).
Why it matters
This randomized controlled trial tested memantine 20 mg daily versus placebo in mild to moderate vascular dementia, not Alzheimer's disease. It provides no information on treating, curing or preventing Alzheimer's disease.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Study designrandomized controlled trial
- Participants579
- Evidence strengthHigh
How this study scored 65/100
Published in a peer-reviewed journal, and it is a meta-analysis pooling many studies. Scored zero for effect reported because the record does not state it. We have no data on senior author's track record, so that was left out: it earned 62 of the 96 points we could judge it on, which is 65 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (International clinical psychopharmacology) |
| Journal's citation record | 1 / 4 | International Clinical Psychopharmacology: journal h-index 128 (OpenAlex, 2026-10-29) |
| Study design | 12 / 12 | A meta-analysis pooling many studies (from PubMed type “Meta-Analysis”) |
| Strength of evidence | 5 / 5 | Rated “high” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2002 — older than 20 years, still counted |
| Sample size | 2 / 4 | 579 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomised / blinded | 0 / 2 | A review of other studies — randomisation is not credited here |
| Times cited | 6 / 7 | Cited 382 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 14.7 citations a year over 26 year(s) since 2002 |
| Impact for its field and year | 4 / 6 | Cited 12.0× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 17 other studies in this library |
| Still being cited | 2 / 4 | Cited 26 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author A. St ffler holds only 1 work(s), too few to judge a track record — left out of this score |
| Institution's track record | 0 / 3 | Frenchay Hospital: institution h-index 262 (OpenAlex) |
| Multi-centre collaboration | 1 / 3 | OpenAlex lists 2 institution(s) in 2 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 12409683) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 62 / 96 | Scored on 19 of 20 parts. We have no data for the rest, so they are left out: 62 of the 96 points we could judge it on is 65 out of 100. |
| Total | 65 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
- DOI: 10.1097/00004850-200211000-00005
- PubMed: 12409683
- Original source →
- Free full text: UWE Research Repository (UWE Bristol) →
Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
17 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Treatments
Also tagged “double-blind”
783 studies in the library carry the topic tag “double-blind”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.